Huang Anmin, Li Ting, Xie Xueting, Xia Jinglin
Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
School of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, China.
Front Mol Biosci. 2021 Nov 25;8:759173. doi: 10.3389/fmolb.2021.759173. eCollection 2021.
Long non-coding RNAs (lncRNAs), which were implicated in many pathophysiological processes including cancer, were frequently dysregulated in hepatocellular carcinoma (HCC). Studies have demonstrated that ferroptosis and immunity can regulate the biological behaviors of tumors. Therefore, biomarkers that combined ferroptosis, immunity, and lncRNA can be a promising candidate bioindicator in clinical therapy of cancers. Many bioinformatics methods, including Pearson correlation analysis, univariate Cox proportional hazard regression analysis, least absolute shrinkage and selection operator (LASSO) analysis, and multivariate Cox proportional hazard regression analysis were applied to develop a prognostic risk signature of immune- and ferroptosis-related lncRNA (IFLSig). Finally, eight immune- and ferroptosis-related lncRNAs (IFLncRNA) were identified to develop and IFLSig of HCC patients. We found the prognosis of patients with high IFLSig will be worse, while the prognosis of patients with low IFLSig will be better. The results provide an efficient method of uniting critical clinical information with immunological characteristics, enabling estimation of the overall survival (OS). Such an integrative prognostic model with high predictive power would have a notable impact and utility in prognosis prediction and individualized treatment strategies.
长链非编码RNA(lncRNAs)参与包括癌症在内的许多病理生理过程,在肝细胞癌(HCC)中经常发生失调。研究表明,铁死亡和免疫可以调节肿瘤的生物学行为。因此,结合铁死亡、免疫和lncRNA的生物标志物可能是癌症临床治疗中有前景的候选生物指标。许多生物信息学方法,包括Pearson相关分析、单变量Cox比例风险回归分析、最小绝对收缩和选择算子(LASSO)分析以及多变量Cox比例风险回归分析,被用于开发免疫和铁死亡相关lncRNA的预后风险特征(IFLSig)。最后,鉴定出8种免疫和铁死亡相关lncRNA(IFLncRNA)以构建HCC患者的IFLSig。我们发现IFLSig高的患者预后较差,而IFLSig低的患者预后较好。这些结果提供了一种将关键临床信息与免疫特征相结合的有效方法,能够估计总生存期(OS)。这种具有高预测能力的综合预后模型在预后预测和个体化治疗策略中将产生显著影响并具有实用价值。